Ann Arbor Stage I B-Cell Non-Hodgkin Lymphoma

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Ann Arbor Stage I B-Cell Non-Hodgkin Lymphoma trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 2 trials

RecruitingPhase 2

NCT04745949

PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With…

This phase II trial studies the effect of brentuximab vedotin and nivolumab alone and in combination with rituximab, cyclophosphamide, doxorubicin, and predniso…

United States31 participantsStarted 2021-05-10

Treatment: Brentuximab Vedotin, Cyclophosphamide

RecruitingEarly Phase 1

NCT04139304

A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma

This feasibility trial studies how well daratumumab in combination with dose-adjusted etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubi…

United States15 participantsStarted 2021-05-24

Treatment: Cyclophosphamide, Daratumumab

All recent trials (11 shown)

Active — Not RecruitingPhase 1/2

NCT00972478

Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or St…

This phase I/II trial is studying the side effects and best dose of vorinostat when given together with rituximab and combination chemotherapy and to see how we…

United States83 participantsStarted 2010-11-15

Treatment: Cyclophosphamide, Doxorubicin Hydrochloride

Active — Not RecruitingPhase 1/2

NCT05025800

ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma

This phase I/II trial finds out the best dose, possible benefits and/or side effects of ALX148 in combination with rituximab and lenalidomide in treating patien…

United States47 participantsStarted 2021-10-13

Treatment: CD47 Antagonist ALX148, Lenalidomide

Ann Arbor Stage I B-Cell Non-Hodgkin Lymphoma

Trial phase breakdown

Trial status

Actively recruiting — 2 trials

PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With…

A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma

All recent trials (11 shown)

Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or St…

ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma

Trial phase breakdown

Trial status

Actively recruiting — 2 trials

PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With…

A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma

All recent trials (11 shown)

Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or St…

ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma

Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma

Ultra Low Dose Orbital Radiation Therapy in Treating Patients With Stage I-IV Indolent B-cell Lymphoma or Mantle Cell Ly…

Treating Young Patients With Newly Diagnosed, Low Stage, Lymphocyte Predominant Hodgkin Disease

Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Ho…

Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymp…

Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver Dysfunctio…